TL;DR
This study introduces the Neurohawk, a new fully radiopaque retriever for mechanical thrombectomy in acute ischemic stroke (AIS). A randomized controlled trial found it to be non-inferior to the established Solitaire FR retriever in terms of successful reperfusion and safety. A sub-analysis also suggests its effectiveness in patients with intracranial atherosclerotic disease (ICAD), a common cause of stroke in Asian populations.
What Problem Does This Paper Address?
Acute ischemic stroke (AIS) caused by large vessel occlusion (LVO) is a time-sensitive medical emergency. Mechanical thrombectomy, using stent-retriever devices to physically remove blood clots, has become a standard treatment. However, visualizing the precise placement and deployment of these devices during the procedure can be challenging, potentially impacting efficacy and safety. Existing retrievers often have limited radiopaque markers, requiring physicians to infer optimal positioning. This study addresses the need for improved visualization during thrombectomy by evaluating a novel, fully radiopaque retriever, the Neurohawk, and comparing its performance against a widely used device, the Solitaire FR. Furthermore, the paper investigates the specific challenges and effectiveness of thrombectomy in patients with intracranial atherosclerotic disease (ICAD), a significant subtype of AIS, particularly in Asian populations, where data on endovascular treatment outcomes are less robust.
Methods
This was a prospective, multicenter, single-blind, randomized, controlled, non-inferiority clinical trial. Patients aged 18-80 with LVO in the anterior circulation were randomly assigned to receive thrombectomy with either the Neurohawk retriever or the Solitaire FR retriever. The primary efficacy endpoint was the rate of successful reperfusion, defined as achieving a modified Thrombolysis In Cerebral Infarction (mTICI) score of 2b or 3. A non-inferiority margin of 12.5% was set. Safety outcomes included symptomatic intracranial hemorrhage (sICH) and all-cause mortality within 90 days. Secondary endpoints included first-pass effect (FPE) and modified FPE. A sub-analysis was performed to compare outcomes in patients with ICAD versus those with other etiologies of LVO.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- Enhanced Visualization: The Neurohawk's "fully radiopaque" design, achieved by incorporating radiopaque wires along its entire struts, offers significantly improved visualization during thrombectomy compared to devices with only a few markers. This allows physicians to better assess device placement and interaction with the thrombus.
- "Push and Fluff" Technique: The enhanced visibility of the Neurohawk potentially enables the use of a "push and fluff" technique, which may lead to better device opening and optimized wall apposition, potentially improving clot capture.
- ICAD Subgroup Importance: The study highlights the prevalence of ICAD-LVO in Asian populations and addresses a critical gap in understanding the efficacy and safety of thrombectomy in this specific patient group. The findings suggest that while ICAD patients may require more rescue measures, the overall outcomes are comparable to non-ICAD patients.
- Potential for Improved Safety: While not statistically significant in this study, the observed trend of a lower sICH rate in the Neurohawk group warrants further investigation.
Key Results
- Non-Inferiority Demonstrated: The Neurohawk retriever was found to be non-inferior to the Solitaire FR in achieving successful reperfusion (88.70% vs. 90.60%, p = 0.867).
- Comparable Safety: Rates of symptomatic intracranial hemorrhage (sICH) were numerically lower in the Neurohawk group (7.02% vs. 13.16%, p = 0.124), though not statistically significant. All-cause mortality within 90 days was also comparable (12.17% vs. 17.09%, p = 0.289).
- Similar Procedural Outcomes: First-pass effect (FPE) and modified FPE rates were similar between the two groups.
- ICAD Subgroup Findings: Patients with ICAD-LVO were younger, had lower initial NIHSS scores, and longer times from onset to puncture. MCA M1 occlusion was more frequent in the ICAD group. While ICAD patients required more rescue measures (e.g., angioplasty/stenting), their successful reperfusion rates and favorable outcomes at 90 days were comparable to non-ICAD patients. Mortality within 90 days was numerically lower in the ICAD group (6.90% vs. 17.24%, p = 0.054).
Limitations and Future Work
The authors acknowledge several limitations:
- Sample Size: The study had a limited sample size, particularly for the ICAD subgroup analysis, which may have limited the statistical power to detect subtle differences.
- Physician Bias: The mRS assessment was conducted by physicians at each center, which could introduce heterogenous judgments.
- Subgroup Analysis Bias: The sub-analysis data were derived from the original trial, potentially introducing selection bias.
- Intraoperative Regimen Heterogeneity: There was heterogeneity in the intraoperative antiplatelet regimen among different centers.
Future work could involve larger, multi-center trials with longer follow-up periods to further confirm the safety and efficacy of the Neurohawk, especially in specific patient populations like those with ICAD. Investigating the impact of the enhanced visualization on procedural efficiency and physician confidence would also be valuable.
Summary updated